Trouble for ecstasy? What MDMA’s FDA setback could mean for psychedelics

In early June, an advisory committee to the FDA voted against the effectiveness on MDMA as a treatment for post-traumatic stress disorder. Drs. Frederick Barrett and Alan Davis comment on the lessons that can be learned from the committee’s stance, viewing it as a learning experience for ongoing studies to follow “the most rigorous methods”.